Compare Kinnevik’s earnings swings with other listed investors under pressure from valuation marks by scanning our hand picked list of solid balance sheet and fundamentals (202 results) for potential alternatives in the same space.
Kinnevik stock asks you to believe in its portfolio of high growth, tech enabled assets rather than smooth quarterly earnings. The recent SEK 218 million profit in Q3 sits against a SEK 6.034b loss over nine months, so the near term story still revolves around valuation marks, exits and currency swings rather than steady profitability.
The key short term catalyst is how quickly underlying holdings convert revenue traction into clearer paths to positive EBITDA and funding self sufficiency. The biggest risk right now is that further FX pressure and multiple compression in software and health assets keep dragging reported net asset value and earnings even when portfolio operations improve.
The latest quarterly report is the most relevant development for that thesis because it shows both sides of Kinnevik’s model in one set of numbers. A single quarter in the black with earnings per share of SEK 0.79 does not offset a SEK 21.79 loss per share year to date, so timing effects remain front and centre.
For catalysts, attention goes to where those fair value moves are coming from, particularly AI enabled software, travel platforms and U.S. digital health. Any evidence in upcoming updates that companies like TravelPerk, Mews, Spring Health or Cityblock are scaling with better unit economics will matter more for the long term narrative than whether Kinnevik reports another profitable quarter.
Kinnevik's analyst narrative projects SEK 2.6 billion of revenue and SEK 2.6 billion of earnings by 2028. These figures are based on an assumption of roughly 149.4% yearly revenue growth and an earnings increase of about SEK 2.5 billion from SEK 124.0 million today.
Uncover why Kinnevik's fair value indicates a 45% potential upside to its current price that could narrow quickly.
One alternate angle on Kinnevik leans hard into Oviva and digital health as a potential accelerator. The most optimistic analysts were pencilling in revenue growth of 153.8% a year and earnings of about SEK 2.7b by 2029 before this earnings release. That is a much brighter story than consensus, and it may shift as you see how these fresh Q3 numbers land.
Explore 2 other Kinnevik fair value estimates, including one that suggests the potential for up to 66% upside from the current price.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis and judgment.
Once you have a clear view on Kinnevik, it can help to compare that thesis against a wider field of opportunities using the Simply Wall St Screener.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com